DPYD (Q12882) variants and mutations
DPYD (also known as Q12882) is a human protein-coding gene encoding a dihydropyrimidine dehydrogenase [NADP(+)] protein. It performs the rate-limiting catabolic step for uracil and thymine and clears most administered fluoropyrimidine drug. Reduced activity can cause dihydropyrimidine dehydrogenase deficiency and markedly increases the risk of severe 5-fluorouracil or capecitabine toxicity. This analysis covers 2,295 DPYD variants and mutations. Of these, 79% have computational variant effect predictions. Disease context includes dihydropyrimidine dehydrogenase deficiency, gastric cancer, and hereditary disease. Example DPYD variants include M1I, M1L, and A2S.
Variant analysis overview
- Gene: DPYD
- Protein: Q12882
- UniProt accession: Q12882
- Organism: Homo sapiens
- Variants analyzed: 2295
- Variant scope: all variants
- Completed: 2026-08-09
Variant and mutation evidence
- Variant composition: 2,030 unspecified-consequence records; 97 synonymous variants; 20 frameshift variants; 135 missense variants; 5 stop-gained variants; 4 in-frame deletions; 1 in-frame insertions; 2 splice-region variants; 1 substitution
- Prediction scores: 1,813 variants have prediction scores (79% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: dihydropyrimidine dehydrogenase deficiency, gastric cancer, hereditary disease, gastric neoplasm, Knee pain, schizophrenia, Wheezing, gastroesophageal reflux disease, intelligence, alcohol drinking, non-small cell lung carcinoma, mathematical ability.
Protein structure and variant hotspots
- Protein features: 3 domains; 36 binding sites; 2 post-translational modification sites.
- Structural context: 248 variants have structural context.
- PTM context: 9 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable DPYD variants
Examples include M1I, M1L, A2S, A2T, A2V, P3S, L5F, S6G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs768020954, ClinGen CA963857, ClinVar RCV000409638, MetaLR 0.53, MetaSVM 0.20, Likely pathogenic, Dihydropyrimidine dehydrogenase deficiency
- M1L (p.Met1Leu), rs772950053, ClinGen CA963858, ClinVar RCV003236367, MetaLR 0.45, MetaSVM -0.04, Likely pathogenic, Dihydropyrimidine dehydrogenase deficiency
- A2S (p.Ala2Ser), rs1232582100, ClinGen CA341379163, ClinVar RCV001106103, TOPMed rs1232582100, REVEL 0.15, MetaLR 0.32, Uncertain significance, Dihydropyrimidine dehydrogenase deficiency
- A2T (p.Ala2Thr), TOPMed rs1232582100, gnomAD rs1232582100, REVEL 0.32, MetaLR 0.45, Uncertain significance, not provided
- A2V (p.Ala2Val), Ensembl rs1674487160, REVEL 0.40, MetaLR 0.49
- P3S (p.Pro3Ser), rs762198241, ClinGen CA963856, ClinVar RCV002739113, ExAC rs762198241, REVEL 0.17, MetaLR 0.26, Uncertain significance, Inborn genetic diseases
- L5F (p.Leu5Phe), gnomAD rs772097379, REVEL 0.42, MetaLR 0.71
- S6G (p.Ser6Gly), TOPMed rs1461963206, gnomAD rs1461963206, REVEL 0.41, MetaLR 0.83
- D8E (p.Asp8Glu), Ensembl rs2101728145, REVEL 0.26, MetaLR 0.40
- D8V (p.Asp8Val), ExAC rs769190350, TOPMed rs769190350, gnomAD rs769190350, REVEL 0.67, MetaLR 0.78
- S9L (p.Ser9Leu), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60082, REVEL 0.13, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- A10E (p.Ala10Glu), gnomAD rs1347103587, REVEL 0.10, MetaLR 0.13
- A10V (p.Ala10Val), gnomAD rs1347103587, REVEL 0.15, MetaLR 0.16
- D11N (p.Asp11Asn), cosmic curated COSV60081, TOPMed rs1236287352, gnomAD rs1236287352, REVEL 0.54, MetaLR 0.56
- I12M (p.Ile12Met), rs376273539, ClinGen CA963852, cosmic curated COSV10003, ClinVar RCV002271942, REVEL 0.57, MetaLR 0.52, Uncertain significance, not specified
- E13K (p.Glu13Lys), rs769820114, ClinGen CA963851, ClinVar RCV003239811, ExAC rs769820114, REVEL 0.42, MetaLR 0.31, Uncertain significance, Inborn genetic diseases
- S14I (p.Ser14Ile), TOPMed rs1672325145, REVEL 0.39, MetaLR 0.35
- L16M (p.Leu16Met), NCI-TCGA Cosmic COSV1000, NCI-TCGA Cosmic COSV6008, cosmic curated COSV60083, Variant assessed as somatic; moderate impact.
- L16P (p.Leu16Pro), ExAC rs764555085, gnomAD rs764555085, REVEL 0.88, MetaLR 0.74
- L16V (p.Leu16Val), ESP rs150036960, ExAC rs150036960, gnomAD rs150036960, REVEL 0.43, MetaLR 0.73
- A17T (p.Ala17Thr), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60080, REVEL 0.33, MetaLR 0.38, Variant assessed as somatic; moderate impact.
- N19Y (p.Asn19Tyr), TOPMed rs1672324131
- P20L (p.Pro20Leu), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60082, Variant assessed as somatic; moderate impact.
- P20R (p.Pro20Arg), ExAC rs753217888, gnomAD rs753217888, REVEL 0.69, MetaLR 0.73
- P20S (p.Pro20Ser), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60083, MetaLR 0.73, MetaSVM 0.58, Variant assessed as somatic; moderate impact.
- R21* (p.Arg21Ter), rs72549310, ClinGen CA199079, cosmic curated COSV10519, ClinVar RCV000169198, CADD 36.00, Pathogenic
- R21Q (p.Arg21Gln), rs80081766, cosmic curated COSV60077, ESP rs80081766, ExAC rs80081766, REVEL 0.44, MetaLR 0.52, Variant assessed as somatic; moderate impact.
- H25L (p.His25Leu), ExAC rs776662759, TOPMed rs776662759, gnomAD rs776662759, REVEL 0.28, MetaLR 0.23
- H25P (p.His25Pro), ExAC rs776662759, TOPMed rs776662759, gnomAD rs776662759, REVEL 0.43, MetaLR 0.34
- H25R (p.His25Arg), ExAC rs776662759, TOPMed rs776662759, gnomAD rs776662759, REVEL 0.27, MetaLR 0.29
- H25Y (p.His25Tyr), rs775601164, ClinGen CA27745029, cosmic curated COSV60076, ClinVar RCV003203365, REVEL 0.30, MetaLR 0.25, Uncertain significance, Inborn genetic diseases
- A26T (p.Ala26Thr), ExAC rs766635900, TOPMed rs766635900, gnomAD rs766635900, REVEL 0.53, MetaLR 0.48
- A26V (p.Ala26Val), TOPMed rs1182593368, gnomAD rs1182593368, REVEL 0.54, MetaLR 0.64
- T27I (p.Thr27Ile), Ensembl rs1672322439, REVEL 0.11, MetaLR 0.21
- T27S (p.Thr27Ser), TOPMed rs770229152, REVEL 0.16, MetaLR 0.08
- C29=, rs1801265, ClinVar RCV000086506, ClinVar RCV004776272, Benign, in DPYDD
- C29R (p.Cys29Arg), rs1801265, ClinGen CA114278, ClinVar RCV000000464, ClinVar RCV000711510, CADD 18.90, PolyPhen-2 0.00, drug response, capecitabine response - Toxicity; fluorouracil response - Toxicity
- C29S (p.Cys29Ser), 1000Genomes rs1801265, ESP rs1801265, ExAC rs1801265, TOPMed rs1801265, Pathogenic, in DPYDD
- C29Y (p.Cys29Tyr), rs528768620, ClinGen CA963802, ClinVar RCV001754147, ExAC rs528768620, REVEL 0.14, CADD 10.50, Uncertain significance, not provided
- S30P (p.Ser30Pro), TOPMed rs1672321595
- T31A (p.Thr31Ala), ExAC rs768501828, TOPMed rs768501828, gnomAD rs768501828, REVEL 0.49, MetaLR 0.52
- T31S (p.Thr31Ser), ExAC rs768501828, TOPMed rs768501828, gnomAD rs768501828, MetaLR 0.28, MetaSVM -0.65
- S32* (p.Ser32Ter), rs748974194, ClinGen CA341380130, ClinVar RCV003467854, AlphaMissense 0.06, MetaLR 0.16, Likely pathogenic
- S32L (p.Ser32Leu), rs748974194, NCI-TCGA Cosmic COSV6007, cosmic curated COSV60077, ExAC rs748974194, REVEL 0.07, AlphaMissense 0.06, Variant assessed as somatic; moderate impact.
- K34E (p.Lys34Glu), ExAC rs769847078, gnomAD rs769847078, REVEL 0.39, MetaLR 0.37
- K34N (p.Lys34Asn), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60084, 1000Genomes rs2101642635, REVEL 0.35, MetaLR 0.40, Variant assessed as somatic; moderate impact.
- K34R (p.Lys34Arg), TOPMed rs1408654214, gnomAD rs1408654214, REVEL 0.26, MetaLR 0.24
- K35N (p.Lys35Asn), TOPMed rs1192820929, gnomAD rs1192820929, MetaLR 0.35, MetaSVM -0.35
- L36* (p.Leu36Ter), Ensembl rs1383125371
- L36V (p.Leu36Val), NCI-TCGA TCGA novel, REVEL 0.17, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- D37G (p.Asp37Gly), TOPMed rs1269099096, gnomAD rs1269099096, REVEL 0.23, MetaLR 0.22
- D37H (p.Asp37His), gnomAD rs984557299, REVEL 0.30, MetaLR 0.22
- D37N (p.Asp37Asn), gnomAD rs984557299, REVEL 0.35, MetaLR 0.12
- K38E (p.Lys38Glu), TOPMed rs1355470366, REVEL 0.72, MetaLR 0.65
- H40P (p.His40Pro), TOPMed rs965757542, gnomAD rs965757542, MetaLR 0.48, MetaSVM -0.07
- H40R (p.His40Arg), TOPMed rs965757542, gnomAD rs965757542, REVEL 0.33, MetaLR 0.35
- K42R (p.Lys42Arg), gnomAD rs1672319464, REVEL 0.52, MetaLR 0.68
- R43G (p.Arg43Gly), ExAC rs780873985, gnomAD rs780873985, REVEL 0.72, MetaLR 0.69
- R43I (p.Arg43Ile), NCI-TCGA Cosmic COSV6007, NCI-TCGA Cosmic COSV6008, cosmic curated COSV60081, MetaLR 0.72, MetaSVM 0.53, Variant assessed as somatic; moderate impact.
- P45S (p.Pro45Ser), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60076, MetaLR 0.14, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- D46A (p.Asp46Ala), rs756684474, ClinGen CA27744966, ClinVar RCV002722932, ExAC rs756684474, REVEL 0.39, MetaLR 0.31, Uncertain significance, Inborn genetic diseases
- D46G (p.Asp46Gly), ExAC rs756684474, TOPMed rs756684474, gnomAD rs756684474, REVEL 0.43, MetaLR 0.41, Uncertain significance
- K47N (p.Lys47Asn), ExAC rs746681994, gnomAD rs746681994, REVEL 0.42, MetaLR 0.35, Uncertain significance, DPYD-related disorder
- N48D (p.Asn48Asp), ExAC rs777238016, TOPMed rs777238016, gnomAD rs777238016, REVEL 0.19, MetaLR 0.11
- N48S (p.Asn48Ser), Ensembl rs1275120039, MetaLR 0.09, MetaSVM -0.98
- C49Y (p.Cys49Tyr), gnomAD rs1672317935, MetaLR 0.66, MetaSVM 0.36
- F50V (p.Phe50Val), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60076, MetaLR 0.11, MetaSVM -0.92, Variant assessed as somatic; moderate impact.
- N51D (p.Asn51Asp), Ensembl rs1669337469, MetaLR 0.08, MetaSVM -0.98
- C52R (p.Cys52Arg), Ensembl rs1012717787, REVEL 0.54, MetaLR 0.41
- C52Y (p.Cys52Tyr), cosmic curated COSV60078, gnomAD rs1312133018, MetaLR 0.71, MetaSVM 0.51
- E53G (p.Glu53Gly), ExAC rs757958938, gnomAD rs757958938, REVEL 0.23, MetaLR 0.16
- E53Q (p.Glu53Gln), gnomAD rs1432796297, REVEL 0.23, MetaLR 0.31
- K54M (p.Lys54Met), Ensembl rs2101480031, MetaLR 0.34, MetaSVM -0.54
- E56* (p.Glu56Ter), TOPMed rs1446753064, CADD 37.00
- F59* (p.Phe59Ter), Ensembl rs2101479957, CADD 33.00
- D60N (p.Asp60Asn), gnomAD rs1160724559, REVEL 0.34, MetaLR 0.34
- D61H (p.Asp61His), rs1557992438, ClinGen CA341379475, ClinVar RCV004376961, AlphaMissense 0.46, MetaLR 0.61, Uncertain significance, Inborn genetic diseases
- D61N (p.Asp61Asn), Ensembl rs1557992438, REVEL 0.55, AlphaMissense 0.46
- I62N (p.Ile62Asn), rs2525245478, ClinGen CA341379465, ClinVar RCV002767712, REVEL 0.85, MetaLR 0.50, Uncertain significance, Inborn genetic diseases
- K63E (p.Lys63Glu), rs367619008, ClinGen CA963770, ClinVar RCV000669112, ClinVar RCV002531218, REVEL 0.70, MetaLR 0.42, Conflicting interpretations, Dihydropyrimidine dehydrogenase deficiency; Inborn genetic diseases; not provide
- K63N (p.Lys63Asn), rs2101479863, ClinGen CA341379455, ClinVar RCV002759292, Ensembl rs2101479863, AlphaMissense 0.97, MetaLR 0.44, Uncertain significance, Inborn genetic diseases
- K63T (p.Lys63Thr), rs2101479885, ClinGen CA341379459, ClinVar RCV002759290, Ensembl rs2101479885, AlphaMissense 0.89, MetaLR 0.36, Uncertain significance, Inborn genetic diseases
- H64P (p.His64Pro), Ensembl rs2101479846, MetaLR 0.37, MetaSVM -0.44, Uncertain significance, Inborn genetic diseases
- T65M (p.Thr65Met), rs371587702, ClinGen CA963768, cosmic curated COSV60084, ClinVar RCV002693628, REVEL 0.58, MetaLR 0.69, Uncertain significance, not provided; Inborn genetic diseases
- T65P (p.Thr65Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T65R (p.Thr65Arg), 1000Genomes rs371587702, ESP rs371587702, ExAC rs371587702, TOPMed rs371587702, REVEL 0.70, MetaLR 0.70, Uncertain significance
- G68C (p.Gly68Cys), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60075, Variant assessed as somatic; moderate impact.
- G68D (p.Gly68Asp), gnomAD rs1444666147, REVEL 0.34, MetaLR 0.33
- E69* (p.Glu69Ter), rs2525245079, ClinGen CA341379423, ClinVar RCV003467837, CADD 38.00, Pathogenic
- E69G (p.Glu69Gly), gnomAD rs1257265643, REVEL 0.64, MetaLR 0.48
- R70* (p.Arg70Ter), rs141597515, ClinGen CA963767, cosmic curated COSV10003, ClinVar RCV000409115, CADD 37.00, Pathogenic
- R70L (p.Arg70Leu), ExAC rs767818267, TOPMed rs767818267, gnomAD rs767818267, REVEL 0.61, MetaLR 0.40, Uncertain significance
- R70Q (p.Arg70Gln), rs767818267, ClinGen CA963766, ClinVar RCV003355047, ExAC rs767818267, REVEL 0.46, MetaLR 0.37, Uncertain significance, Inborn genetic diseases
- A72N (p.Ala72Asn), rs2525244930, ClinGen CA2695198095, ClinVar RCV003467847, Likely pathogenic
- A72P (p.Ala72Pro), Ensembl rs1571426976, REVEL 0.84, MetaLR 0.84
- A72T (p.Ala72Thr), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, Ensembl rs1571426976, REVEL 0.74, MetaLR 0.81, Variant assessed as somatic; moderate impact.
- L73F (p.Leu73Phe), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60084, Variant assessed as somatic; moderate impact.
- L73R (p.Leu73Arg), rs762102298, ClinGen CA963765, ClinVar RCV002425548, ExAC rs762102298, REVEL 0.74, MetaLR 0.62, Uncertain significance, Inborn genetic diseases
- R74* (p.Arg74Ter), rs189768576, ClinGen CA963764, cosmic curated COSV10590, ClinVar RCV000411323, CADD 37.00, Pathogenic
- R74Q (p.Arg74Gln), cosmic curated COSV60074, TOPMed rs1669331541, REVEL 0.38, MetaLR 0.18
- A76V (p.Ala76Val), ExAC rs765131182, gnomAD rs765131182, REVEL 0.82, MetaLR 0.73
- M77V (p.Met77Val), 1000Genomes rs527580106, ExAC rs527580106, TOPMed rs527580106, gnomAD rs527580106, REVEL 0.05, MetaLR 0.09
- R78* (p.Arg78Ter), rs776692894, ClinGen CA963761, NCI-TCGA Cosmic COSV6008, cosmic curated COSV60080, CADD 41.00, Likely pathogenic
- R78S (p.Arg78Ser), gnomAD rs1167788637
- C79F (p.Cys79Phe), gnomAD rs1474728674, REVEL 0.96, MetaLR 0.97
- C79Y (p.Cys79Tyr), cosmic curated COSV10942, NCI-TCGA TCGA novel, MetaLR 0.97, MetaSVM 1.09, Variant assessed as somatic; moderate impact.
- L80V (p.Leu80Val), gnomAD rs1392368213, REVEL 0.71, MetaLR 0.61
- C82F (p.Cys82Phe), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, MetaLR 0.97, MetaSVM 1.09, Variant assessed as somatic; moderate impact.
- D84E (p.Asp84Glu), Ensembl rs1571280156, REVEL 0.59, MetaLR 0.62
- A85S (p.Ala85Ser), ExAC rs757342874, gnomAD rs757342874, REVEL 0.69, MetaLR 0.73
- A85T (p.Ala85Thr), ExAC rs757342874, gnomAD rs757342874, REVEL 0.80, MetaLR 0.77
- P86A (p.Pro86Ala), Ensembl rs1664201160
- P86L (p.Pro86Leu), rs568132506, ClinGen CA963745, cosmic curated COSV10737, ClinVar RCV001329029, REVEL 0.85, MetaLR 0.65, Pathogenic/Likely pathogenic, not provided; Dihydropyrimidine dehydrogenase deficiency
- P86R (p.Pro86Arg), 1000Genomes rs568132506, ExAC rs568132506, TOPMed rs568132506, gnomAD rs568132506, MetaLR 0.70, MetaSVM 0.42, Pathogenic
- C87F (p.Cys87Phe), cosmic curated COSV60081, 1000Genomes rs528152707, ExAC rs528152707, gnomAD rs528152707, REVEL 0.96, MetaLR 1.00
- Q88R (p.Gln88Arg), gnomAD rs938680293, REVEL 0.71, MetaLR 0.54, Uncertain significance, Inborn genetic diseases
- K89* (p.Lys89Ter), rs672601289, ClinGen CA228177, ClinVar RCV000086502, TOPMed rs672601289, AlphaMissense 0.65, MetaLR 0.32
- K89E (p.Lys89Glu), TOPMed rs672601289, REVEL 0.62, AlphaMissense 0.65
- S90I (p.Ser90Ile), rs672601288, ClinGen CA228172, ClinVar RCV000086501, Ensembl rs672601288, AlphaMissense 0.78, MetaLR 0.64, not provided
- C91F (p.Cys91Phe), rs928681171, ClinGen CA27656042, ClinVar RCV003419171, TOPMed rs928681171, REVEL 0.94, MetaLR 1.00, Uncertain significance, DPYD-related disorder
- C91Y (p.Cys91Tyr), TOPMed rs928681171, gnomAD rs928681171, MetaLR 1.00, MetaSVM 0.91, Uncertain significance
- P92A (p.Pro92Ala), rs143986398, ClinGen CA963742, cosmic curated COSV60079, ClinVar RCV000991926, REVEL 0.97, MetaLR 0.97, Uncertain significance, Dihydropyrimidine dehydrogenase deficiency; not provided
- P92L (p.Pro92Leu), TOPMed rs1332016862, MetaLR 0.97, MetaSVM 1.08
- P92T (p.Pro92Thr), ESP rs143986398, ExAC rs143986398, TOPMed rs143986398, gnomAD rs143986398, REVEL 0.97, MetaLR 0.97, Uncertain significance
- T93S (p.Thr93Ser), ExAC rs760553268, gnomAD rs760553268, REVEL 0.72, MetaLR 0.68
- N94I (p.Asn94Ile), gnomAD rs1228947466, REVEL 0.60, MetaLR 0.39
- L95I (p.Leu95Ile), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60076, Variant assessed as somatic; moderate impact.
- D96H (p.Asp96His), ExAC rs773159364, TOPMed rs773159364, gnomAD rs773159364, REVEL 0.65, MetaLR 0.69
- D96N (p.Asp96Asn), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60075, MetaLR 0.59, MetaSVM 0.24, Variant assessed as somatic; moderate impact.
- D96V (p.Asp96Val), rs771573678, NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, ExAC rs771573678, REVEL 0.84, MetaLR 0.73, Variant assessed as somatic; moderate impact.
- I97T (p.Ile97Thr), ESP rs375990187, TOPMed rs375990187, REVEL 0.93, MetaLR 0.71
- I97V (p.Ile97Val), TOPMed rs1664197872, REVEL 0.28, MetaLR 0.25
- S99L (p.Ser99Leu), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60077, MetaLR 0.23, MetaSVM -0.73, Variant assessed as somatic; moderate impact.
- F100L (p.Phe100Leu), ExAC rs774047246, TOPMed rs774047246, gnomAD rs774047246, MetaLR 0.64, MetaSVM 0.43
- I101T (p.Ile101Thr), TOPMed rs1664196479, REVEL 0.92, MetaLR 0.72
- I104M (p.Ile104Met), rs749699298, NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, ExAC rs749699298, REVEL 0.72, MetaLR 0.53, Variant assessed as somatic; moderate impact.
- I104V (p.Ile104Val), ExAC rs768288280, gnomAD rs768288280, REVEL 0.29, MetaLR 0.40
- A105S (p.Ala105Ser), ESP rs150385342, ExAC rs150385342, gnomAD rs150385342, MetaLR 0.27, MetaSVM -0.55
- A105T (p.Ala105Thr), ESP rs150385342, ExAC rs150385342, gnomAD rs150385342, REVEL 0.25, MetaLR 0.28
- A105V (p.Ala105Val), TOPMed rs1664195715, gnomAD rs1664195715, REVEL 0.42, MetaLR 0.34
- N106K (p.Asn106Lys), TOPMed rs1264310175, REVEL 0.35, MetaLR 0.26
- N108D (p.Asn108Asp), gnomAD rs1485319921, REVEL 0.57, MetaLR 0.57
- N108K (p.Asn108Lys), gnomAD rs762430779, REVEL 0.57, MetaLR 0.55
- Y109C (p.Tyr109Cys), gnomAD rs1312400771, REVEL 0.89, MetaLR 0.72
- Y109N (p.Tyr109Asn), TOPMed rs1212037891, gnomAD rs1212037891, REVEL 0.81, MetaLR 0.72
- Y109S (p.Tyr109Ser), gnomAD rs1312400771, REVEL 0.91, MetaLR 0.74
- Y110H (p.Tyr110His), rs1283205838, ClinGen CA341376697, ClinVar RCV003146860, gnomAD rs1283205838, REVEL 0.57, MetaLR 0.44, Uncertain significance, Dihydropyrimidine dehydrogenase deficiency
- G111E (p.Gly111Glu), ExAC rs762533012, gnomAD rs762533012, REVEL 0.55, MetaLR 0.54
- G111R (p.Gly111Arg), rs1201456521, NCI-TCGA Cosmic COSV6007, cosmic curated COSV60075, gnomAD rs1201456521, AlphaMissense 0.76, MetaLR 0.74, Variant assessed as somatic; moderate impact.
- A112D (p.Ala112Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A112G (p.Ala112Gly), TOPMed rs1662931643, MetaLR 0.71, MetaSVM 0.52
- K114E (p.Lys114Glu), rs2524539694, ClinGen CA341376673, ClinVar RCV003201386, Uncertain significance, Inborn genetic diseases
- K114N (p.Lys114Asn), ESP rs370615432, ExAC rs370615432, TOPMed rs370615432, gnomAD rs370615432, MetaLR 0.43, MetaSVM -0.14, Likely benign
- M115I (p.Met115Ile), rs377169736, NCI-TCGA Cosmic COSV6007, cosmic curated COSV60078, NCI-TCGA Cosmic COSV6008, REVEL 0.05, MetaLR 0.03, Uncertain significance, not provided; Dihydropyrimidine dehydrogenase deficiency
- M115V (p.Met115Val), ESP rs141462178, ExAC rs141462178, TOPMed rs141462178, gnomAD rs141462178, REVEL 0.03, MetaLR 0.03
- I116M (p.Ile116Met), Ensembl rs1662930809, REVEL 0.70, MetaLR 0.53
- I116T (p.Ile116Thr), gnomAD rs1662930987, REVEL 0.90, MetaLR 0.66
- I116V (p.Ile116Val), gnomAD rs1054239986, REVEL 0.38, MetaLR 0.57
- S118F (p.Ser118Phe), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, MetaLR 0.62, MetaSVM 0.31, Variant assessed as somatic; moderate impact.
- D119E (p.Asp119Glu), ExAC rs777348913, gnomAD rs777348913, REVEL 0.61, MetaLR 0.54
- N120K (p.Asn120Lys), gnomAD rs942607291, REVEL 0.78, MetaLR 0.79
- N120S (p.Asn120Ser), rs771534236, NCI-TCGA Cosmic COSV6008, cosmic curated COSV60082, ExAC rs771534236, REVEL 0.64, MetaLR 0.67, Variant assessed as somatic; moderate impact.
- N120T (p.Asn120Thr), ExAC rs771534236, TOPMed rs771534236, gnomAD rs771534236, REVEL 0.64, MetaLR 0.73
- L122I (p.Leu122Ile), gnomAD rs1344975302, REVEL 0.67, MetaLR 0.60
- L122V (p.Leu122Val), gnomAD rs1344975302, REVEL 0.72, MetaLR 0.65
- G123C (p.Gly123Cys), NCI-TCGA Cosmic COSV6007, cosmic curated COSV60075, Variant assessed as somatic; moderate impact.
- G123S (p.Gly123Ser), rs778022685, ClinGen CA963707, ClinVar RCV002869619, ExAC rs778022685, REVEL 0.62, MetaLR 0.53, Uncertain significance, Inborn genetic diseases
- L124V (p.Leu124Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T125A (p.Thr125Ala), Ensembl rs1662929621
- G127* (p.Gly127Ter), NCI-TCGA Cosmic COSV6007, Variant assessed as somatic; high impact.
- G127E (p.Gly127Glu), NCI-TCGA Cosmic COSV1000, cosmic curated COSV10003, Variant assessed as somatic; moderate impact.
- G127R (p.Gly127Arg), cosmic curated COSV60079, ExAC rs758514990
- V129G (p.Val129Gly), ExAC rs748320430, TOPMed rs748320430, gnomAD rs748320430, REVEL 0.92, MetaLR 0.80
- T132I (p.Thr132Ile), ExAC rs750224169, gnomAD rs750224169, REVEL 0.70, MetaLR 0.72
- T132S (p.Thr132Ser), 1000Genomes rs538336580, ExAC rs538336580, gnomAD rs538336580, REVEL 0.73, MetaLR 0.73
- S133C (p.Ser133Cys), TOPMed rs1662928505
- S133F (p.Ser133Phe), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60083, REVEL 0.73, MetaLR 0.76, Variant assessed as somatic; moderate impact.
- D134V (p.Asp134Val), NCI-TCGA Cosmic COSV6008, cosmic curated COSV60080, MetaLR 0.58, MetaSVM 0.17, Variant assessed as somatic; moderate impact.
- L135F (p.Leu135Phe), rs1411615618, NCI-TCGA Cosmic COSV6007, cosmic curated COSV60079, gnomAD rs1411615618, REVEL 0.55, MetaLR 0.55, Variant assessed as somatic; moderate impact.
- C136S (p.Cys136Ser), 1000Genomes rs2101026394, REVEL 0.96, MetaLR 1.00
Public DPYD analysis runs
- DPYD analysis run — DPYD (2,295 variants) — completed 2026-08-09